Covid-19 vaccine (comirnaty original/omicron ba 4-5 mrna vaccine)
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Vaccine containing COVID-19 (Comirnaty Original/Omicron BA 4-5 MRNA).
Coronavirus disease 2019 (COVID-19): Prophylaxis
For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.
Available at https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book
COVID-19 Vaccine (Comirnaty Original/Omicron BA 4-5 MRNA vaccine) is indicated for individuals who have previously received at least a primary vaccination course against COVID-19.
1 dose (0.3ml).
Children aged 12 years and older
1 dose (0.3ml).
Administered via intramuscular injection, preferably into the deltoid muscle.
Children under 12 years
Severe febrile conditions
Precautions and Warnings
Recent anticoagulant therapy
Postpone immunisation if there is active or suspected infection
Impaired response possible in immunocompromised patients
Vaccine may not be effective in 100% of patients
Contains polyethylene glycol
Do not mix with other vaccines in the same syringe
Record name and batch number of administered product
Resuscitation facilities must be immediately available
Monitor patient for at least 15 minutes after vaccination
Advise patient to inform their physician if dyspnoea/chest pain occur
Advise patient to report signs or symptoms of myocarditis and pericarditis
Advise patient to seek medical attention if new onset of heart palpitations
Increased risk of myocarditis and pericarditis
Management of cases of shock should follow current medical standards
Follow national immunisation guidelines
Myocarditits and pericarditis can develop with a few days after vaccination, and have occurred primarily within 14 days, and observed more often after the second vaccination and in younger males.
If anaphylaxis occurs following the first dose of the vaccine, do not administer the second dose.
Precautions should be in place to avoid injury from fainting should a psychogenic response occur from the needle injection.
Pregnancy and Lactation
COVID-19 Vaccine (Comirnaty Original-Omicron BA 4-5 MRNA) is considered safe for use during pregnancy.
The manufacturer advises COVID-19 Vaccine (Comirnaty Original-Omicron BA 4-5 MRNA) may be used during pregnancy. At the time of writing there is limited published information regarding the use of COVID-19 Vaccine (Comirnaty Original-Omicron BA 4-5 MRNA) during pregnancy. Potential risks are unknown.
COVID-19 Vaccine (Comirnaty Original-Omicron BA 4-5 MRNA) is considered safe for use during breastfeeding.
The manufacturer states COVID-19 Vaccine (Comirnaty Original-Omicron BA 4-5 MRNA) may be used safely during breastfeeding. The presence of COVID-19 Vaccine (Comirnaty Original-Omicron BA 4-5 MRNA) in breast milk is unknown. Effects on exposed infants are unknown.
Injection site reactions
Local pain (injection site)
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: January 2023
Summary of Product Characteristics: Comirnaty Original/Omicron BA. 4-5 (15/15 micrograms)/ dose dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified). Pfizer Ltd. Revised November 2022.
Immunisation against infectious disease (The Green Book).
Available at: https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book
Last revised: 05 September 2022
Last accessed: 30 January 2023
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.